创模生物科技(北京)有限公司

CN / En

NEWS

Introducing the InnoModels Biotechnology IC50 Cell Activity Assay Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-29 16:04
  • Views:

(Summary description)The IC50 Cell Activity Assay Platform of InnoModels Biotechnology (Beijing) Co., Ltd. is a professional service platform integrating years of experience in cell culture and IC50 assay. The platform was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University, and is dedicated to providing high-quality and reliable cell activity assay services to help research and development of oncology and tumor immunotherapy.

Introducing the InnoModels Biotechnology IC50 Cell Activity Assay Platform

(Summary description)The IC50 Cell Activity Assay Platform of InnoModels Biotechnology (Beijing) Co., Ltd. is a professional service platform integrating years of experience in cell culture and IC50 assay. The platform was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University, and is dedicated to providing high-quality and reliable cell activity assay services to help research and development of oncology and tumor immunotherapy.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-29 16:04
  • Views:
Information

Platform Overview
The IC50 Cell Activity Assay Platform of InnoModels Biotechnology (Beijing) Co., Ltd. is a professional service platform integrating years of experience in cell culture and IC50 assay. The platform was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University, and is dedicated to providing high-quality and reliable cell activity assay services to help research and development of oncology and tumor immunotherapy.
Team and Experience
InnoModels Biotechnology has a laboratory team with over 15 years of experience in IC50 and cell culture. The laboratory staff not only possesses profound professional knowledge, but also specializes in IC50 assay and cell culture technology, and is able to provide professional services to customers in the field of cell activity assay. The platform emphasizes data quality and experimental safety. All cells are tested for STR (Short Tandem Repeat Sequence) before use to ensure the accuracy of cell identity, and are regularly tested for mycoplasma and chlamydia in the cell culture solution to ensure the reliability and safety of the experiments.

 


Cell Resources
The platform has over 400 human-derived tumor cell lines covering a wide range of cancer types and subtypes. This means that researchers can easily select the cell line that suits their research needs, whether for anticancer drug screening or mechanistic studies. This rich cellular resource provides researchers with great convenience and promotes in-depth and extensive research.
Experimental Procedures and Standards
InnoModels' IC50 cell activity assay platform strictly follows a standardized experimental process to ensure that the results of each experiment are credible. The experimental process usually includes steps such as customer ordering online, order/experiment material confirmation, cell processing, MTT stain preparation, MTT incubation (or CCK-8 incubation), DMSO lysis, OD value determination, IC50 calculation and issuance of experiment report. Through this process, the platform can provide customers with high-quality cell activity data to support their research work.
Meaning and application of IC50
IC50 is the concentration of inhibitor when the response is inhibited by half, and is an important measure of antagonist drug potency in pharmacological studies. In the context of apoptosis, IC50 can be understood as the concentration required for a certain concentration of a drug to induce 50% apoptosis in tumor cells. The lower the value, the greater the ability of the drug to induce apoptosis and, inversely, the degree of tolerance of a given cell to the drug.The IC50 value is usually expressed as a molar concentration (mol/L or M) and is determined by a functional assay or a competition binding assay.
In drug screening and efficacy assessment, IC50 is an important indicator of drug cytotoxicity or cellular tolerance to a drug. By calculating the cellular inhibition rate at successive different administered concentrations, a dose response curve can be plotted to estimate the IC50 value. This value is important for evaluating the efficacy and safety of drugs and optimizing drug dosage.
Advanced Technology and Services
In addition to IC50 assays, Transmooker provides a variety of advanced experimental techniques and services, such as CDC (Complement-Dependent Cell Killing Effect Assessment), ADCC (Antibody-Dependent Cell-Mediated Cell Killing Response Measurement), and T-cell-mediated killing assays. These technologies and services are capable of simulating and evaluating the effects of drugs on tumor cells in vitro, providing key insights into immunotherapeutic strategies.
Conclusion
With its abundant cell resources, professional experimental team, standardized experimental process and advanced experimental technology, the InnoModels Biotechnology IC50 cell activity assay platform provides researchers with high-quality and reliable cell activity assay services. The platform is committed to assisting the research and development of tumor and tumor immunotherapy, and promoting the progress and development of medical research. If you have any questions about the platform's services or need further information, please feel free to contact our team.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司